Eli Lilly's Experimental Cancer Drug Cuts Recurrence Risk In Early-Stage Lung Cancer Patients

Eli Lilly and Co.(NYSE:LLY) on Monday shared positive topline results from the Phase 3 LIBRETTO-432 clinical trial for Retevmo (selpercatinib).

The trial demonstrated a highly statistically significant improvement in event-free survival for patients with early-stage non-small cell lung cancer.

Lung Cancer Trial Shows Benefit

The LIBRETTO-432 trial results showed that selpercatinib significantly reduced the risk of disease recurrence or death in patients with RET fusion-positive non-small cell lung cancer.

Don't Miss:

Fast Company Calls It a ‘Groundbreaking Step for the Creator Economy' — Investors Can Still Get In at $0.85/Share Before the IPO: How One Company Quietly Locked Up 500+ Iconic Character Rights

This trial is the first randomized Phase 3 study evaluating a selective RET kinase inhibitor as adjuvant therapy, reinforcing the value of genomic testing in cancer treatment.

In addition, the overall safety profile of selpercatinib was consistent with previous studies, and detailed results are expected to be presented at an upcoming medical congress. The trial enrolled 151 patients who received either selpercatinib or placebo, marking a significant step in the treatment of early-stage lung cancer.

The broader market experienced a mixed day on the previous trading day, with the S&P 500 futures down 0.4% while the Healthcare sector remained unchanged.

Eli Lilly’s gains come as the Healthcare sector is currently ranked 8 out of 11 sectors, indicating mid-tier performance.

Trending: Blue-chip art has historically outpaced the S&P 500 since 1995, and fractional investing is now opening this institutional asset class to everyday investors.

Technical Analysis

Eli Lilly shares have increased 21.33% over the past 12 months, reflecting a strong upward trend. Currently, the stock is trading above its key support level of $1033.50 and is positioned closer to its 52-week highs than lows, suggesting continued strength in its price action.

The RSI is at a neutral level, indicating that the stock is neither overbought nor oversold at this time. Meanwhile, the MACD is also neutral, suggesting a balanced momentum without strong bullish or bearish pressure.

The combination of neutral RSI and MACD suggests mixed momentum, indicating that traders should watch for potential breakout or reversal signals in the near term.

Key Resistance: $1088.50 Key Support: $1033.50

Analyst Consensus & Recent Actions:

The stock carries a Buy Rating with an average price target of $1141.70. Recent analyst moves include:

Deutsche Bank: Buy (Raises Target to $1285) JP Morgan: Overweight (Raises Target to $1300) Cantor Fitzgerald: Overweight (Raises Target to $1205)

Story Continues

See Also: Own a Stake in California's New Standard for Luxury Behavioral Health

Benzinga Edge Rankings

The Benzinga Edge scorecard for Eli Lilly highlights its strengths and weaknesses compared to the broader market:

Value Rank: 3.49 — Indicates the stock is trading at a premium relative to peers. Quality Rank: 90.9 — Suggests a strong balance sheet and operational efficiency. Momentum Rank: 84.91 — Reflects strong price performance relative to the market.

The Verdict: Eli Lilly’s Benzinga Edge signal reveals a strong momentum score, indicating that the stock is outperforming the broader market. However, the low value rank suggests that investors should be cautious of potential overvaluation.

Top ETF Exposure

Capital Group Dividend Value ETF (NYSE:CGDV): 6.06% Weight Simplify Health Care ETF (NYSE:PINK): 7.46% Weight Dana Unconstrained Equity ETF (NYSE:DUNK): 7.58% Weight

Read Next: This Under-$1 Pre-IPO AI Company Is Still Open to Retail Investors — Learn More

Photo via Shutterstock

UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.

Get the latest stock analysis from Benzinga:

APPLE (AAPL): Free Stock Analysis Report TESLA (TSLA): Free Stock Analysis Report

This article Eli Lilly's Experimental Cancer Drug Cuts Recurrence Risk In Early-Stage Lung Cancer Patients originally appeared on Benzinga.com

View Comments